ACADIA Pharmaceuticals Inc Q2 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gavin Scott - JPMorgan Chase & Co, Research Division - Analyst : This is Gavin on for Cory. Just curious, did the FDA clarify what particular analysis needs to be completed to convince them? Or what do you think you can show them to be convincing?

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Steve, just on the Type A meeting. I know coming into that meeting you were really striving for an understanding of why the FDA appeared to have changed their position there. I'm just curious, coming out of that now, if you felt as though you've reached that understanding and as you've alluded to, kind of, the alignment path forward. What that means for getting on a firmer footing with them with the next steps? And then just secondly, on a separate topic just related to BD. Just curious if you could update us on sort of your criteria there, especially as maybe the wider industry has been prompted to rethink assets and development plans following the aducanumab approval?

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Sure, Steve. Just I'm curious if you could just update us on the criteria that you're applying when you look at external assets and just curious if some of the aducanumab approval while it's prompted others in the sector to maybe rethink how to look at assets and development programs, if that applies to you as well? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 04, 2021 / 8:30PM, ACAD.OQ - Q2 2021 ACADIA Pharmaceuticals Inc Earnings Call